Back to Journals » Breast Cancer: Targets and Therapy » Volume 8

Adjuvant systemic therapy in older women with breast cancer

Authors Leone J, Leone BA, Leone J

Received 18 April 2016

Accepted for publication 24 May 2016

Published 25 July 2016 Volume 2016:8 Pages 141—147

DOI https://doi.org/10.2147/BCTT.S110765

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Professor Pranela Rameshwar

Julieta Leone,1 Bernardo Amadeo Leone,1 José Pablo Leone2

1Department of Medical Oncology, Grupo Oncológico Cooperativo del Sur (GOCS), Neuquén, Argentina; 2Department of Internal Medicine, Division of Hematology-Oncology and Blood & Marrow Transplantation, University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA

Abstract: Breast cancer in the elderly is an increasing clinical problem. In addition, ~60% of deaths from breast cancer occur in women aged 65 years and older. Despite this, older women with breast cancer have been underrepresented in clinical trials, and this has led to less than optimal evidence to guide their therapy. The management of elderly women with early breast cancer is a complex process that requires careful evaluation of life expectancy, comorbidities, patient values, and risks and benefits of available treatment options. This review will focus on current adjuvant systemic therapy options for older women with breast cancer, discuss the principles in the decision-making process, and define the role of endocrine therapy, chemotherapy, and targeted agents.

Keywords: breast cancer, adjuvant therapy, chemotherapy, endocrine therapy, elderly

A Letter to the Editor has been received and published for this article.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine

Recondo G Jr, de la Vega M, Galanternik F, Díaz-Cantón E, Leone BA, Leone JP

Cancer Management and Research 2016, 8:57-65

Published Date: 19 May 2016